- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | J&J halts huge study of experimental RSV vaccine and kills program in surprise decision | ||
| Mi | No longer 'dead or just hibernating,' drugmakers return to heart medicines | ||
| Mi | AstraZeneca axes license agreement with Aridis, placing Europe-funded PhIII on hold | ||
| Mi | European investment group closes €260M raise for dementia fund | ||
| Mi | FDA lifts partial hold on Blueprint's CDK2 inhibitor | ||
| Di | Vanda wins court case against FDA over disclosure of CRL details for sleep drug | ||
| Di | Ohio attorney general sues several PBMs over antitrust concerns | ||
| Di | House committee chair requests info from FDA on funding for trials involving 'viral manipulation' | ||
| Di | Pharma ad total tops $8B again in 2022, led by top brands from Sanofi and Regeneron, AbbVie | ||
| Di | FDA plans upcoming adcomms for OTC contraceptive, epinephrine nasal spray, Intarcia's last shot | ||
| Di | House committee to investigate FDA's response to ongoing drug shortages | ||
| Di | MarketingRx roundup: AbbVie drives endometriosis awareness; Novartis adds to Cosentyx campaign | ||
| Di | Q&A: Pfizer corporate communications chief Sally Susman discusses book crafted in pandemic and personal lessons | ||
| Di | Ferring closes key research site, letting go 89 workers in San Diego | ||
| Di | Biomea Fusion stock soars on early-stage diabetes data | ||
| Di | Tiny multiomics biotech secures former J&J drug, new execs and new financing | ||
| Di | Intra-Cellular Therapies gets a boost on PhIII depression drug data | ||
| Di | Evotec's CNS deal with Bristol Myers gets $50M infusion and eight-year extension | ||
| Di | Viking soars on early-stage weight loss data as it maps out PhII | ||
| Di | Novartis rides with Bicycle for new pact on targeted radiotherapies | ||
| Di | With Boehringer Ingelheim's help, Roivant churns out another Vant to go up against Endeavor, Impact founders | ||
| Di | Gunning for 2023 approval, GSK details PhIII data for Jemperli in frontline endometrial cancer | ||
| Di | AbbVie drops CytomX partnership, leaving PhII program in the air | ||
| Di | Jeffrey Bluestone brings his startup haul to $400M+, joining forces with Regeneron on cell therapies | ||
| Di | Applied Molecular Transport prepares to close up shop as it pauses R&D, replaces CEO, lays off 57% |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
